Choice-based trial of RA medicines with filgotinib or TNFi
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 4 study compares two treatment options for rheumatoid arthritis (RA): filgotinib or a TNF inhibitor (TNFi). It is designed for adults whose current “standard” RA tablets have not worked well or were not tolerated, to see which approach improves RA control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign the study consent form.
- You have adult-onset rheumatoid arthritis (RA) for at least 3 months.
- You have been taking at least one standard RA tablet (csDMARD) for at least 3 months, and it hasn’t worked or you couldn’t tolerate it.
- Your RA activity is moderate to severe (for example, DAS28 of at least 3.2 at screening/baseline).
- You have been on a stable dose of csDMARD tablets for at least 4 weeks before the study starts.
- You have not used any biologic or targeted “newer” RA medicine before (no biologic DMARDs or JAK inhibitors), and you don’t have untreated/active tuberculosis or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two RA medications, filgotinib and adalimumab, to see how they affect your body's proteins and genetic signals. It may help your doctor know which treatment is better for your type of RA.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This trial uses a very high-strength brain MRI to understand how the RA medicine filgotinib may reduce pain. If you have active rheumatoid arthritis and can safely complete the scan, the study may help researchers better target pain relief in RA.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.